Clincosm LogoSign in Get a demo

Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement

Sponsor
Greater Houston Retina Research (Other)
Overall Status
Completed
CT.gov ID
NCT03531294
Collaborator
Regeneron Pharmaceuticals (Industry), The Cleveland Clinic (Other)
40
Enrollment
2
Locations
2
Arms
34.6
Actual Duration (Months)
20
Patients Per Site
0.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The PRIME trial will assess the safety of 2 mg intravitreal aflibercept injections (IAI) to achieve and maintain DRSS improvements (2 or more steps) in patients with a baseline DRSS level of 47A to 71A inclusive through 104 weeks as determined by reading center determined DRSS gradings on OPTOS fundus photos and leakage index on OPTOS WF-FA.

Condition or Disease Intervention/Treatment Phase
  • Drug: Aflibercept Injection
 Phase 2

Detailed Description

Study eyes will be assigned randomly (1:1 ratio) to one of the following 2 treatment arms. Randomization of PDR subjects will be limited to 50% of each arm.

Group 1

Year 1 Subjects will be seen every month, 28 days (+ 7 days), for 52 weeks. All subjects will receive IAI at baseline, after eligibility is confirmed. Week 4 through week 48, subjects will be seen monthly and treated with IAI PRN (pro re nata) according to, same day, central reading center (CRC) determined DRSS level. Monthly treatment with IAI will continue until a greater than or equal to 2 step DRSS level improvement is achieved, relative to screening/baseline DRSS based on CRC assessment OPTOS fundus photos (FP). Subjects who have baseline proliferative diabetic retinopathy (PDR) (DRSS Level 61-71) will continue to receive monthly IAI until a greater than or equal to 2 step DRSS improvement is achieved as determined by CRC assessment of OPTOS fundus photos relative to screening/baseline DRSS, and PDR is quiescent according to the treating investigator. Treatment with IAI will be reinitiated if a 1 step worsening of DRSS occurs compared to best DRSS score achieved, determined by CRC evaluation of OPTOS fundus photos. If such worsening is detected, the subject would resume monthly IAI until best DRSS score or greater is achieved, as determined by CRC assessment of OPTOS fundus photos. In addition, retreatment will also be re-started if new onset neovascularization is identified and is continued until the PDR is quiescent according to the treating investigator.

Year 2 Beginning in year 2 (week 52) subjects will be seen every 56 days (+ 14 days) and treated with IAI PRN (pro re nata) utilizing the same criteria from year 1. All subjects will have a mandatory week 104 visit, where treatment will not be given.

Group 2

Year 1 Subjects will be seen every month, 28 days (+ 7 days), for 52 weeks. All subjects will receive IAI at baseline, after eligibility is confirmed. Week 4 through week 48, subjects will be seen monthly and treated with IAI PRN (pro re nata) according to, same day, CRC determination of DRSS initially, and subsequently of leakage index.

Monthly treatment with IAI will continue until a greater than or equal to 2 step DRSS level improvement is achieved, relative to screening/baseline DRSS based on CRC assessment OPTOS fundus photos (FP). Subjects who have baseline proliferative diabetic retinopathy (PDR) (DRSS Level 61-71) will continue to receive monthly IAI until a greater than or equal to 2 step DRSS improvement is achieved as determined by CRC assessment of OPTOS fundus photos relative to screening/baseline DRSS, and PDR is quiescent according to the treating investigator.

Leakage index as determined by CRC assessment of OPTOS WF-FA at the visit at which a greater than or equal to 2 step DRSS level improvement is achieved will be considered the threshold. Treatment with IAI will be reinitiated if the leakage index increases to 33% above the individual subject threshold leakage index level as determined by CRC evaluation of OPTOS WF-FA. If such worsening is detected, the subject would resume monthly IAI until the threshold leakage index as determined by CRC assessment of OPTOS WF-FA is reached. In addition, retreatment will also be re-started if new onset neovascularization is identified and is continued until the PDR is quiescent according to the treating investigator.

Year 2 Beginning in year 2 (week 52) subjects will be seen every 56 days (+ 14 days) and treated with IAI PRN (pro re nata) utilizing the same criteria from year 1. All subjects will have a mandatory week 104 visit, where treatment will not be given.

If images of insufficient quality are unable to be obtained, in Group 1 or Group 2, subjects will undergo treatment with IAI at principal investigators discretion or designee.

Subjects can have both eyes in the study, if eligibility is met. If both eyes are eligible, one eye will be randomized to group 1 while the other is randomized to group 2. If only one eye is eligible IAI will be provided for the fellow eye as needed according to the treating investigator.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
Actual Study Start Date :
May 23, 2018
Actual Primary Completion Date :
Apr 9, 2021
Actual Study Completion Date :
Apr 9, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group 1

Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based on OPTOS funds photos.

Drug: Aflibercept Injection
intravitreal 2mg aflibercept injection
Other Names:
  • Eyela

    		•
    Experimental: Group 2

    Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based leakage index of OPTOS wide field fluorescein angiography.

    Drug: Aflibercept Injection
    intravitreal 2mg aflibercept injection
    Other Names:
  • Eyela

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of Adverse Events for diabetic retinopathy subjects who receive intravitreal Aflibercept [104 weeks]

      Assess the safety of 2 mg intravitreal aflibercept injections (IAI) to achieve and maintain DRSS improvements (2 or more steps) in patients with a baseline DRSS level of 47A to 71A inclusive as determined by reading center determined DRSS gradings on OPTOS fundus photos and leakage index on OPTOS WF-FA

    Secondary Outcome Measures

    1. Correlation of DRSS and leakage index [104 weeks]

      Correlation of reading-center determined DRSS level and leakage index to determine change in DR severity

    2. Correlation between Reading Center DRSS Level and Physician determined DR severity [104 weeks]

      Correlation of reading-center determined DRSS level and investigator-determined DR severity level based on ophthalmoscopic fundus examination (Physician determined DR severity level will be based on AAO (American Academy of Ophthalmology) simplified grading system: mild NPDR, moderate NPDR, Severe NPDR, low risk PDR, high risk PDR)

    3. Number of IAI [104 weeks]

      Mean and Median number of IVT aflibercept Injections (with and without IAI given for DME)

    4. Mean number of IAI (NPDR VS PDR) [104 weeks]

      Mean number of IVT aflibercept Injections in eyes with baseline NPDR vs PDR through week 52

    5. ETDRS-BCVA change [104 weeks]

      Mean change in Early Treatment Diabetic Retinopathy Study best corrected visual acuity (ETDRS-BCVA)

    6. Changes in Visual Function [104 weeks]

      Changes in visual function outcomes as measured by National Eye Institute Visual Functioning Questionnaire (NEI-VFQ)

    7. DRSS Change [104 weeks]

      Changes in DRSS

    8. Change in Non-Perfusion [104 weeks]

      Change in area of retinal non-perfusion within the macula and periphery

    9. Change in Vascular Leakage [104 weeks]

      Change in relative area of vascular leakage on wide-field fluorescein angiography

    10. Change in microaneurysms [104 weeks]

      Change in number of microaneurysms, assessed by wide-field fluorescein angiography

    11. Change in CST [104 weeks]

      Mean change in central subfield thickness (CST), as assessed by spectral Domain Optical coherence tomography (SD-OCT)

    12. DME development [104 weeks]

      Percentage of subjects, who develop center-involving diabetic macular edema necessitating treatment compared to baseline

    13. PDR Development [104 weeks]

      Percentage of subjects, who develop a new PDR event compared to baseline

    14. Cytokine Levels [104 weeks]

      Corelation of cytokine levels in aqueous humor samples to clinical and imaging outcomes

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Men or Women > 18 years of age with type 1 or II diabetes mellitus

    2. Diabetic Retinopathy, DRSS Level 47A to 71A, as assessed by CRC (enrollment of PDR levels will be limited to 50% of the total population)

    3. BCVA in the study eye better than 20/800

    Exclusion Criteria:

    1. Any prior systemic anti-VEGF treatment or IVT anti-search vascular endothelial growth factor (VEGF) treatment in the study eye within 24 weeks of screening/baseline

    2. Any intravitreal or peribulbar corticosteroids in the study eye within 12 weeks of screening/baseline

    3. Any prior treatment with Ozurdex or Iluvien in the study eye

    4. SD-OCT central subfield thickness (CST) > 320 µm in the study eye

    5. Central DME causing visual acuity loss, in which treatment can not be safely deferred for at least 6 months, in the investigator's judgment

    6. Current visually significant vitreous hemorrhage in the study eye. Vitreous hemorrhage is allowed as long as DRSS level is 71A or lower.

    7. History of panretinal photocoagulation (PRP) in the study eye

    8. History of vitrectomy surgery in the study eye

    9. Cataract surgery in the study eye within 8 weeks of screening/baseline

    10. Pregnant or breast-feeding women

    11. Sexually active men* or women of childbearing potential** who are unwilling to practiceadequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening/baseline; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly).

    • Contraception is not required for men with documented vasectomy.

    ** Postmenopausal women must be amenorrheic for at least 52 weeks in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

    1. If currently receiving diaylisis, must have started treatment more than 12 weeks prior to screening/baseline

    2. Uncontrolled blood pressure (defined as > 190/110 mm Hg systolic/diastolic, while seated)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Retina Consultants of Houston/The Medical Center Houston Texas United States 77030
    2 Retina Consultants of Houston The Woodlands Texas United States 77384

    Sponsors and Collaborators

    • Greater Houston Retina Research
    • Regeneron Pharmaceuticals
    • The Cleveland Clinic

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Greater Houston Retina Research
    ClinicalTrials.gov Identifier:
    NCT03531294
    Other Study ID Numbers:
    • PRIME
    First Posted:
    May 21, 2018
    Last Update Posted:
    May 21, 2021
    Last Verified:
    May 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Retinal Diseases
    Diabetic Retinopathy
    Aflibercept

    Study Results

    No Results Posted as of May 21, 2021